Literature DB >> 17942517

Influence of oligoclonal IgM specificity in multiple sclerosis disease course.

Lm Villar1, N García-Barragán, M Espiño, E Roldán, Mc Sádaba, J Gómez-Rial, P González-Porqué, Jc Alvarez-Cermeño.   

Abstract

Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis (MS) course. However, the clinical significance of OCMB without lipid specificity, present in other MS patients, remains unknown. We describe here a characterization of these antibodies and study their role in MS progression. Fifty-four MS patients showing CSF-restricted OCMB were included in this study at disease onset and followed-up during 61.1 +/- 2.7 months. The specificity of OCMB and the CSF B-cell profile were investigated. A second CSF IgM study was performed in a group of eight patients. Thirty-eight patients showed OCMB against myelin lipids (M+L+) and other sixteen had OCMB lacking this specificity (M+L-). The CD5+ B cell subpopulation, responsible for most persistent IgM responses, was considerably higher in M+L+ than in M+L- patients (3.3 +/- 0.6% versus 0.8 +/- 0.2, P = 0.009). In addition, M+L+ bands persisted during disease course, while M+L- disappeared during follow-up. M+L+ patients suffered more relapses (4.2 +/- 0.6 versus 1.6 +/- 0.3, P = 0.002) and reached higher disability (EDSS score of 2.2 +/- 0.2 versus 1.2 +/- 0.2, P = 0.02) than M+L- group. These data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942517     DOI: 10.1177/1352458507082046

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  23 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.

Authors:  Bonaventura Casanova; Laura Lacruz; María Luisa Villar; José Andrés Domínguez; María Carcelén Gadea; Francisco Gascón; Javier Mallada; David Hervás; María Simó-Castelló; José Carlos Álvarez-Cermeño; Carmen Calles; Javier Olascoaga; Lluís Ramió-Torrentà; Carmen Alcalá; Angeles Cervelló; Isabel Boscá; Francisco Carlos Pérez-Mirallles; Francisco Coret
Journal:  Neurol Sci       Date:  2018-06-07       Impact factor: 3.307

Review 3.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

4.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Authors:  Jessica Frau; Luisa Maria Villar; Claudia Sardu; Maria Antonietta Secci; Lucia Schirru; Diana Ferraro; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Roberta Bedin; Patrizia Sola; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2017-12-22       Impact factor: 4.849

5.  Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome.

Authors:  Diana Ferraro; Veronica Galli; Anna Maria Simone; Roberta Bedin; Francesca Vitetta; Elisa Merelli; Paolo Frigio Nichelli; Patrizia Sola
Journal:  J Neurovirol       Date:  2016-11-22       Impact factor: 2.643

6.  Primary progressive multiple sclerosis and generalized myasthenia gravis: an uncommon association.

Authors:  G Bigliardi; J Mandrioli; F Valzania; P Nichelli; N Casula; A M Simone; P Sola
Journal:  Neurol Sci       Date:  2010-06-29       Impact factor: 3.307

Review 7.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

8.  Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.

Authors:  Maria José Magraner; Isabel Bosca; Maria Simó-Castelló; Gracian García-Martí; Angel Alberich-Bayarri; Francisco Coret; Jose C Alvarez-Cermeño; Luís Martí-Bonmatí; Luisa M Villar; Bonaventura Casanova
Journal:  Neuroradiology       Date:  2011-02-16       Impact factor: 2.804

9.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

10.  Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP.

Authors:  Chris J Hedegaard; Ning Chen; Finn Sellebjerg; Per Soelberg Sørensen; R Graham Q Leslie; Klaus Bendtzen; Claus H Nielsen
Journal:  Immunology       Date:  2008-12-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.